GlassScriptPhysician profile
Yitzchok B Kurtzer
NPI 1154321891
$18,482.19
in general payments reported to CMS, 2019-2025
57 companies · $54.84 in 2025
The $54.84 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,935 · 2020: $2,472 · 2021: $1,748 · 2022: $3,371 · 2023: $4,056 · 2024: $2,846 · 2025: $54.84.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,915 · Education: $41.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,915.33 |
| Education | $41.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $3,106.30 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,613.31 | 2020-2024 | |
| Novo Nordisk INC | $1,251.78 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,182.76 | 2019-2024 | Relistor, Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,169.72 | 2019-2025 | Jardiance, Synjardy, Stiolto Respimat |
| Janssen Pharmaceuticals, INC | $864.75 | 2019-2022 | |
| Glaxosmithkline, LLC. | $796.40 | 2019-2023 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $733.48 | 2021-2024 | |
| Kowa Pharmaceuticals America, INC. | $701.95 | 2019-2024 | Livalo, Seglentis, Zoryve |
| Amgen INC. | $569.23 | 2019-2021 | |
| Paratek Pharmaceuticals, INC. | $562.06 | 2022-2024 | Nuzyra |
| Merck Sharp & Dohme LLC | $544.81 | 2019-2023 | Verquvo, Belsomra |
| Pfizer INC. | $357.24 | 2019-2023 | |
| Lilly USA, LLC | $353.20 | 2020-2024 | Jardiance, Mounjaro |
| Astellas Pharma US INC | $336.59 | 2019-2021 |
Show all 57 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yitzchok Kurtzer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.